The stock was at $1.07 on Tuesday morning, or about 9.8 times last 12 month EBITDA on S&P Global Markets Research data.
While it’s just numbers, Jefferies isn’t the institutional equities shop looking at Virtus Health for a read on Monash IVF. There’s a bunch of small cap managers on Monash IVF’s register who also wouldn’t mind a big bid.
Monash IVF is the second biggest fertility clinics group in Australia with an estimated 25.3 per cent market share, according to IBIS World. Virtus is the biggest with 39.5 per cent, while only other major players is Genea (12.6 per cent).
Australia’s BGH Capital and London-based CapVest have both made indicative bids for Virtus Health. CapVest is in exclusive due diligence, while BGH Capital has asked the Takeovers Panel to help level the playing field.